A Phase 3 interventional study of CPL-01 and saline placebo in Postoperative Pain and Bunion, sponsored by Cali Pharmaceuticals LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Cali Pharmaceuticals LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.
Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 356th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 11 that started in 2027, is one of 162 in phase 3, reaches primary completion later than 138 of the 235 other live ones, and was the 1,138th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Columbia University · Sites in United States
Ages 12–21
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Women only
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 155 · Phase 3 179 · Phase 4 359
First in 1996; this study’s year is marked. 11 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 112 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 1,098 interventional studies, 130 across the 82 observational. Of the 784 that completed or were terminated, 474 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
199 of 1,180 have an industry lead sponsor. The 10 most frequent:
Cali Pharmaceuticals LLC is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Cali Pharmaceuticals LLC has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
97 of the studies in Pain, Postoperative with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060495Phase 3Rutgers, The State University of New JerseyRADA16 for Adult Tonsillectomy | 2026-12-01 |
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 1,180 studies in Pain, Postoperative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with a bunion will have that repaired and then pain and rescue medicine use will be evaluated.
After signing an informed consent and then appropriate screening and meeting the inclusion and exclusion criteria, patients will have their bunion repaired under regional anesthesia. They will then stay in the facility for 72 hours while pain, rescue medication, and other criteria are assessed. A follow-up visit will occur at 7 days and 30 days after.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intra-operative local administration
Drug: CPL-01
Intra-operative local administration
Drug: saline placebo
Administration by the Surgeon during the operation
Administration by the Surgeon during the operation
Postoperative Pain with activity
AUC NRS-A wWOCF (Area Under the Curve of the Numeric Rating Scale sore for pain with Activity where 0 is no pain and 10 is worst pain imaginable)
Time frame: 24 hours
Postoperative Pain with rest
AUC NRS-R wWOCF (Area Under the Curve of the Numeric Rating Scale sore for pain at Rest where 0 is no pain and 10 is worst pain imaginable)
Time frame: 24 hours, 72 hours
Postoperative rescue medication use
Opioid and non-opioid pain control medicines needed
Time frame: 24 hours, 72 hours
Plan to share: Yes — All IPD necessary for results
Supporting information: Study protocol
Time frame: After approval
Access criteria: As necessary
Start is estimated for Mar 2027; primary completion for Jun 2027, 3 months later.
Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 3 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Jul 2026 → Mar 2027, primary completion Oct 2026 → Jun 2027 and completion Nov 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CPL-01
Cali Pharmaceuticals LLC